Why is hypertension considered a risk factor for myocardial infarction and subsequently heart failure?

1. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12(1):10–38. [PubMed] [Google Scholar]

2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines(Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154–e235. [PubMed] [Google Scholar]

3. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115(5):e69–171. [PubMed] [Google Scholar]

4. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106(24):3068–3072. [PubMed] [Google Scholar]

5. Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. 2005;47(5):320–332. [PubMed] [Google Scholar]

6. O’Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. 1994;13(4):S107–S112. [PubMed] [Google Scholar]

7. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88(1):107–115. [PubMed] [Google Scholar]

8. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397–1402. [PubMed] [Google Scholar]

9. Kenchaiah S, Narula J, Vasan RS. Risk factors for heart failure. Med Clin North Am. 2004;88(5):1145–1172. [PubMed] [Google Scholar]

10. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347(5):305–313. [PubMed] [Google Scholar]

11. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807–1816. [PubMed] [Google Scholar]

12. Gillum RF. Epidemiology of heart failure in the United States. Am Heart J. 1993;126(4):1042–1047. [PubMed] [Google Scholar]

13. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285(26):1441–1446. [PubMed] [Google Scholar]

14. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651–1658. [PubMed] [Google Scholar]

15. Bourassa MG, Gurne O, Bangdiwala SI, Ghali JK, Young JB, Rousseau M, et al. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction(SOLVD) Investigators. J Am Coll Cardiol. 1993;22(4 Suppl A):14A–19A. [PubMed] [Google Scholar]

16. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341(12):857–865. [PubMed] [Google Scholar]

17. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003;107(11):1562–1566. [PubMed] [Google Scholar]

18. Tuzcu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 2001;103(22):2705–2710. [PubMed] [Google Scholar]

19. Mohri M, Takeshita A. Coronary microvascular disease in humans. Jpn Heart J. 1999;40(2):97–108. [PubMed] [Google Scholar]

20. Poulsen SH, Jensen SE, Egstrup K. Longitudinal changes and prognostic implications of left ventricular diastolic function in first acute myocardial infarction. Am Heart J. 1999;137(5):910–918. [PubMed] [Google Scholar]

21. Humphrey LS, Topol EJ, Rosenfeld GI, Borkon AM, Baumgartner WA, Gardner TJ, et al. Immediate enhancement of left ventricular relaxation by coronary artery bypass grafting: intraoperative assessment. Circulation. 1988;77(4):886–896. [PubMed] [Google Scholar]

22. Bonow RO, Vitale DF, Bacharach SL, Frederick TM, Kent KM, Green MV. Asynchronous left ventricular regional function and impaired global diastolic filling in patients with coronary artery disease: reversal after coronary angioplasty. Circulation. 1985;71(2):297–307. [PubMed] [Google Scholar]

23. Hochman JS, Boland J, Sleeper LA, Porway M, Brinker J, Col J, et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality. Results of an International Registry. SHOCK Registry Investigators. Circulation. 1995;91(3):873–881. [PubMed] [Google Scholar]

24. Lavie CJ, Gersh BJ. Mechanical and electrical complications of acute myocardial infarction. Mayo Clin Proc. 1990;65(5):709–730. [PubMed] [Google Scholar]

25. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101(25):2981–2988. [PubMed] [Google Scholar]

26. Wijns W, Vatner SF, Camici PG. Hibernating myocardium. N Engl J Med. 1998;339(3):173–181. [PubMed] [Google Scholar]

27. Kloner RA, Przyklenk K. Hibernation and stunning of the myocardium. N Engl J Med. 1991;325(26):1877–1879. [PubMed] [Google Scholar]

28. Bolli R. Myocardial ‘stunning’ in man. Circulation. 1992;86(6):1671–1691. [PubMed] [Google Scholar]

29. Auerbach MA, Schoder H, Hoh C, Gambhir SS, Yaghoubi S, Sayre JW, et al. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation. 1999;99(22):2921–2926. [PubMed] [Google Scholar]

30. Wei L, Kadoya M, Momose M, Kurozumi M, Matsushita T, Yamada A. Serial assessment of left ventricular function in various patient groups with Tl-201 gated myocardial perfusion SPECT. Radiat Med. 2007;25(2):65–72. [PubMed] [Google Scholar]

31. Bell SP, Fabian J, Watkins MW, LeWinter MM. Decrease in forces responsible for diastolic suction during acute coronary occlusion. Circulation. 1997;96(7):2348–2352. [PubMed] [Google Scholar]

32. Firstenberg MS, Smedira NG, Greenberg NL, Prior DL, McCarthy PM, Garcia MJ, et al. Relationship between early diastolic intraventricular pressure gradients, an index of elastic recoil, and improvements in systolic and diastolic function. Circulation. 2001;104(12 Suppl 1):I330–I335. [PubMed] [Google Scholar]

33. Uren NG, Melin JA, De Bruyne B, Wijns W, Baudhuin T, Camici PG. Relation between myocardial blood flow and the severity of coronary-artery stenosis. N Engl J Med. 1994;330(25):1782–1788. [PubMed] [Google Scholar]

34. Di Carli M, Czernin J, Hoh CK, Gerbaudo VH, Brunken RC, Huang SC, et al. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation. 1995;91(7):1944–1951. [PubMed] [Google Scholar]

35. Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20(6):421–428. [PubMed] [Google Scholar]

36. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998;97(3):282–289. [PubMed] [Google Scholar]

37. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–1562. [PubMed] [Google Scholar]

38. Uretsky BF, Thygesen K, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival(ATLAS) trial. Circulation. 2000;102(6):611–616. [PubMed] [Google Scholar]

39. Repetto A, Dal Bello B, Pasotti M, Agozzino M, Vigano M, Klersy C, et al. Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: an innocent bystander? Eur Heart J. 2005;26(15):1519–1527. [PubMed] [Google Scholar]

40. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077–1084. [PubMed] [Google Scholar]

41. Hedrich O, Jacob M, Hauptman PJ. Progression of coronary artery disease in non-ischemic dilated cardiomyopathy. Coron Artery Dis. 2004;15(5):291–297. [PubMed] [Google Scholar]

42. Graf S, Khorsand A, Gwechenberger M, Novotny C, Kletter K, Sochor H, et al. Typical chest pain and normal coronary angiogram: cardiac risk factor analysis versus PET for detection of microvascular disease. J Nucl Med. 2007;48(2):175–181. [PubMed] [Google Scholar]

43. Qian JY, Ge JB, Fan B, Wang QB, Chen HZ, Baumgart D, et al. Identification of syndrome X using intravascular ultrasound imaging and Doppler flow mapping. Chin Med J(Engl) 2004;117(4):521–527. [PubMed] [Google Scholar]

44. Bart BA, Shaw LK, McCants CB, Jr, Fortin DF, Lee KL, Califf RM, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol. 1997;30(4):1002–1008. [PubMed] [Google Scholar]

45. Felker GM, Shaw LK, O’Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol. 2002;39(2):210–218. [PubMed] [Google Scholar]

46. Purek L, Laule-Kilian K, Christ A, Klima T, Pfisterer ME, Perruchoud AP, et al. Coronary artery disease and outcome in acute congestive heart failure. Heart. 2006;92(5):598–602. [PMC free article] [PubMed] [Google Scholar]

47. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502. [PubMed] [Google Scholar]

48. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327(10):669–677. [PubMed] [Google Scholar]

49. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet. 1992;340(8829):1173–1178. [PubMed] [Google Scholar]

50. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46(3):425–431. [PubMed] [Google Scholar]

51. Janosi A, Ghali JK, Herlitz J, Czuriga I, Klibaner M, Wikstrand J, et al. Metoprolol CR/XL in postmyocardial infarction patients with chronic heart failure: experiences from MERIT-HF. Am Heart J. 2003;146(4):721–728. [PubMed] [Google Scholar]

52. The Acute Infarction Ramipril Efficacy(AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342(8875):821–828. [PubMed] [Google Scholar]

53. O’Connor CM, Velazquez EJ, Gardner LH, Smith PK, Newman MF, Landolfo KP, et al. Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy(a 25-year experience from the Duke Cardiovascular Disease Databank) Am J Cardiol. 2002;90(2):101–107. [PubMed] [Google Scholar]

54. Alderman EL, Fisher LD, Litwin P, Kaiser GC, Myers WO, Maynard C, et al. Results of coronary artery surgery in patients with poor left ventricular function(CASS) Circulation. 1983;68(4):785–795. [PubMed] [Google Scholar]

55. Baker DW, Jones R, Hodges J, Massie BM, Konstam MA, Rose EA. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. JAMA. 1994;272(19):1528–1534. [PubMed] [Google Scholar]

56. Pigott JD, Kouchoukos NT, Oberman A, Cutter GR. Late results of surgical and medical therapy for patients with coronary artery disease and depressed left ventricular function. J Am Coll Cardiol. 1985;5(5):1036–1045. [PubMed] [Google Scholar]

57. Elefteriades JA, Tolis G, Jr, Levi E, Mills LK, Zaret BL. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol. 1993;22(5):1411–1417. [PubMed] [Google Scholar]

58. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med. 1969;71(1):89–105. [PubMed] [Google Scholar]

59. Kannel WB, Dannenberg AL, Levy D. Population implications of electrocardiographic left ventricular hypertrophy. Am J Cardiol. 1987;60(17):85I–93I. [PubMed] [Google Scholar]

60. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med. 1988;108(1):7–13. [PubMed] [Google Scholar]

61. Urbina EM, Gidding SS, Bao W, Pickoff AS, Berdusis K, Berenson GS. Effect of body size, ponderosity, and blood pressure on left ventricular growth in children and young adults in the Bogalusa Heart Study. Circulation. 1995;91(9):2400–2406. [PubMed] [Google Scholar]

62. Inouye I, Massie B, Loge D, Topic N, Silverstein D, Simpson P, et al. Abnormal left ventricular filling: an early finding in mild to moderate systemic hypertension. Am J Cardiol. 1984;53(1):120–126. [PubMed] [Google Scholar]

63. Smith VE, Schulman P, Karimeddini MK, White WB, Meeran MK, Katz AM. Rapid ventricular filling in left ventricular hypertrophy: II. Pathologic hypertrophy. J Am Coll Cardiol. 1985;5(4):869–874. [PubMed] [Google Scholar]

64. Pearson AC, Gudipati C, Nagelhout D, Sear J, Cohen JD, Labovitz AJ. Echocardiographic evaluation of cardiac structure and function in elderly subjects with isolated systolic hypertension. J Am Coll Cardiol. 1991;17(2):422–430. [PubMed] [Google Scholar]

65. Devereux RB. Left ventricular diastolic dysfunction: early diastolic relaxation and late diastolic compliance. J Am Coll Cardiol. 1989;13(2):337–339. [PubMed] [Google Scholar]

66. Brucks S, Little WC, Chao T, Kitzman DW, Wesley-Farrington D, Gandhi S, et al. Contribution of left ventricular diastolic dysfunction to heart failure regardless of ejection fraction. Am J Cardiol. 2005;95(5):603–606. [PubMed] [Google Scholar]

67. Marcus ML, Harrison DG, Chilian WM, Koyanagi S, Inou T, Tomanek RJ, et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation. 1987;75(1 Pt 2):I19–I25. [PubMed] [Google Scholar]

68. Gandhi SK, Powers JC, Nomeir AM, Fowle K, Kitzman DW, Rankin KM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001;344(1):17–22. [PubMed] [Google Scholar]

69. Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, et al. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112(25):3958–3968. [PubMed] [Google Scholar]

70. Vasan RS, Larson MG, Leip EP, Evans JC, O’Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291–1297. [PubMed] [Google Scholar]

71. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252. [PubMed] [Google Scholar]

72. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288(14):1723–1727. [PubMed] [Google Scholar]

73. Kostis JB, Davis BR, Cutler J, Grimm RH, Jr, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278(3):212–216. [PubMed] [Google Scholar]

74. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension(STOP-Hypertension) Lancet. 1991;338(8778):1281–1285. [PubMed] [Google Scholar]

75. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996;27(5):1214–1218. [PubMed] [Google Scholar]

76. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med. 1996;156(16):1789–1796. [PubMed] [Google Scholar]

77. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):14–53. [PubMed] [Google Scholar]

78. The SOLVD Investigattors. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685–691. [PubMed] [Google Scholar]

79. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001;104(14):1615–1621. [PubMed] [Google Scholar]

80. Ingelsson E, Bjorklund-Bodegard K, Lind L, Arnlov J, Sundstrom J. Diurnal blood pressure pattern and risk of congestive heart failure. JAMA. 2006;295(24):2859–2866. [PubMed] [Google Scholar]

81. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D’Agostino RB, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA. 2002;287(8):1003–1010. [PubMed] [Google Scholar]

82. Staessen JA, Gasowski J, Wang JG, Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355(9207):865–872. [PubMed] [Google Scholar]

83. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993;153(5):598–615. [PubMed] [Google Scholar]

84. Brush JE, Jr, Cannon RO, III, Schenke WH, Bonow RO, Leon MB, Maron BJ, et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med. 1988;319(20):1302–1307. [PubMed] [Google Scholar]

85. Bache RJ, Arentzen CE, Simon AB, Vrobel TR. Abnormalities in myocardial perfusion during tachycardia in dogs with left ventricular hypertrophy: metabolic evidence for myocardial ischemia. Circulation. 1984;69(2):409–417. [PubMed] [Google Scholar]

86. Zhang J, Merkle H, Hendrich K, Garwood M, From AH, Ugurbil K, et al. Bioenergetic abnormalities associated with severe left ventricular hypertrophy. J Clin Invest. 1993;92(2):993–1003. [PMC free article] [PubMed] [Google Scholar]

87. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92(3):657–671. [PubMed] [Google Scholar]

88. Giannattasio C, Mangoni AA, Failla M, Carugo S, Stella ML, Stefanoni P, et al. Impaired radial artery compliance in normotensive subjects with familial hypercholesterolemia. Atherosclerosis. 1996;124(2):249–260. [PubMed] [Google Scholar]

89. van der Linde NA, Sijbrands EJ, Boomsma F, van den Meiracker AH. Effect of low-density lipoprotein cholesterol on angiotensin II sensitivity: a randomized trial with fluvastatin. Hypertension. 2006;47(6):1125–1130. [PubMed] [Google Scholar]

90. Leibovitz E, Beniashvili M, Zimlichman R, Freiman A, Shargorodsky M, Gavish D. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am J Hypertens. 2003;16(9 Pt 1):715–718. [PubMed] [Google Scholar]

91. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994;89(6):2519–2524. [PubMed] [Google Scholar]

92. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351(1):33–41. [PubMed] [Google Scholar]

93. Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, et al. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample. Hypertension. 2007;49(4):846–856. [PubMed] [Google Scholar]

94. Kathiresan S, Larson MG, Benjamin EJ, Corey D, Murabito JM, Fox CS, et al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am J Hypertens. 2005;18(5 Pt 1):657–665. [PubMed] [Google Scholar]

95. Kathiresan S, Gona P, Larson MG, Vita JA, Mitchell GF, Tofler GH, et al. Cross-sectional relations of multiple biomarkers from distinct biological pathways to brachial artery endothelial function. Circulation. 2006;113(7):938–945. [PubMed] [Google Scholar]

96. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355(25):2631–2639. [PubMed] [Google Scholar]

97. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104(22):2746–2753. [PubMed] [Google Scholar]

98. Kannel WB. Lessons from curbing the coronary artery disease epidemic for confronting the impending epidemic of heart failure. Med Clin North Am. 2004;88(5):1129–33. ix. [PubMed] [Google Scholar]

Why is hypertension a risk factor for heart failure?

Does hypertension increases the risk of myocardial infarction and stroke?

How are hypertension and heart failure related?

Is hypertension associated with myocardial infarction?